LT3590942T - Hepatito b viruso paviršinio antigeno inhibitorius - Google Patents

Hepatito b viruso paviršinio antigeno inhibitorius

Info

Publication number
LT3590942T
LT3590942T LTEPPCT/CN2018/078581T LT18763490T LT3590942T LT 3590942 T LT3590942 T LT 3590942T LT 18763490 T LT18763490 T LT 18763490T LT 3590942 T LT3590942 T LT 3590942T
Authority
LT
Lithuania
Prior art keywords
hepatitis
surface antigen
virus surface
antigen inhibitor
inhibitor
Prior art date
Application number
LTEPPCT/CN2018/078581T
Other languages
English (en)
Inventor
Fei Sun
Jinhua Du
Yanbin Hu
Lili Zhou
Charles Z. Ding
Shuhhui CHEN
Original Assignee
Fujian Cosunter Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Cosunter Pharmaceutical Co., Ltd. filed Critical Fujian Cosunter Pharmaceutical Co., Ltd.
Publication of LT3590942T publication Critical patent/LT3590942T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LTEPPCT/CN2018/078581T 2017-03-09 2018-03-09 Hepatito b viruso paviršinio antigeno inhibitorius LT3590942T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710138275 2017-03-09
PCT/CN2018/078581 WO2018161960A1 (zh) 2017-03-09 2018-03-09 乙型肝炎病毒表面抗原抑制剂

Publications (1)

Publication Number Publication Date
LT3590942T true LT3590942T (lt) 2021-07-12

Family

ID=63447286

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/CN2018/078581T LT3590942T (lt) 2017-03-09 2018-03-09 Hepatito b viruso paviršinio antigeno inhibitorius

Country Status (25)

Country Link
US (1) US11008331B2 (lt)
EP (1) EP3590942B1 (lt)
JP (1) JP6783424B2 (lt)
KR (1) KR102087397B1 (lt)
CN (1) CN109071564B (lt)
AU (1) AU2018232071B2 (lt)
BR (1) BR112019018650B1 (lt)
CA (1) CA3055442C (lt)
DK (1) DK3590942T3 (lt)
EA (1) EA038122B9 (lt)
ES (1) ES2879930T3 (lt)
HR (1) HRP20211331T1 (lt)
HU (1) HUE055170T2 (lt)
IL (1) IL269142B (lt)
LT (1) LT3590942T (lt)
MX (1) MX374497B (lt)
MY (1) MY174224A (lt)
PH (1) PH12019502052B1 (lt)
PL (1) PL3590942T3 (lt)
PT (1) PT3590942T (lt)
RS (1) RS62094B1 (lt)
SG (1) SG11201908101YA (lt)
SI (1) SI3590942T1 (lt)
WO (1) WO2018161960A1 (lt)
ZA (1) ZA201906252B (lt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183266A1 (en) 2015-05-13 2016-11-17 Enanta Pharmaceuticals, Inc. Ehpatitis b antiviral agents
KR102398439B1 (ko) 2016-03-07 2022-05-16 이난타 파마슈티칼스, 인코포레이티드 B형 간염 항바이러스제
CN110066278B (zh) 2017-06-01 2021-06-08 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019169539A1 (en) * 2018-03-05 2019-09-12 Pharmaresources (Shanghai) Co., Ltd. Novel oxa-and aza-tricyclic 4-pyridone-3-carboxylic acid for treatment and prophylaxis of hepatitis b virus infection
WO2019191166A1 (en) 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CN110862390B (zh) 2018-08-28 2023-05-09 广东东阳光药业有限公司 稠合三环类化合物及其在药物中的应用
US20210330678A1 (en) * 2018-09-05 2021-10-28 Children`S Medical Center Corporation Papd5 inhibitors and methods of use thereof
JP2022500466A (ja) 2018-09-21 2022-01-04 エナンタ ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としての官能化複素環
CN110964023B (zh) 2018-09-30 2022-12-27 广东东阳光药业有限公司 稠合四环类化合物及其在药物中的应用
IL283190B2 (en) 2018-11-21 2025-08-01 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
WO2020247575A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021052447A1 (zh) * 2019-09-19 2021-03-25 福建广生堂药业股份有限公司 一种乙肝表面抗原抑制剂的晶型及其应用
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
JP7706475B2 (ja) * 2020-05-15 2025-07-11 福建▲広▼生中霖生物科技有限公司 三環式化合物を含む組み合わせ及びhbv治療薬物の製造におけるその使用
JP2023526345A (ja) * 2020-05-15 2023-06-21 福建▲広▼生中霖生物科技有限公司 B型肝炎の治療に使用される組み合わせ
WO2022112207A1 (en) * 2020-11-25 2022-06-02 F. Hoffmann-La Roche Ag Aromatic spiro ring amide derivatives for the treatment and prophylaxis of hepatitis b virus infection
CN116744932B (zh) * 2021-01-15 2025-08-08 福建广生中霖生物科技有限公司 一种手性噁嗪类化合物的制备方法
WO2026052081A1 (zh) * 2024-09-06 2026-03-12 福建广生中霖生物科技有限公司 用于治疗乙型肝炎的药物及组合

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130251647A1 (en) 2011-09-20 2013-09-26 Basf Se Low molecular weight modulators of the cold menthol receptor trpm8 and use thereof
CN103450184A (zh) 2012-05-29 2013-12-18 上海壹志医药科技有限公司 斯氏紫堇碱衍生物的盐
EA201691261A1 (ru) * 2014-01-30 2016-11-30 Ф. Хоффманн-Ля Рош Аг Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
HK1244281B (zh) * 2015-02-11 2020-02-07 F. Hoffmann-La Roche Ag 治疗和预防乙型肝炎病毒感染的2-氧代-6,7-二氢苯并[a]喹嗪-3-甲酸衍生物
CN107849037B (zh) 2015-07-21 2020-04-17 豪夫迈·罗氏有限公司 用于治疗和预防乙型肝炎病毒感染的三环4-吡啶酮-3-甲酸衍生物
WO2017017043A1 (en) * 2015-07-28 2017-02-02 F. Hoffmann-La Roche Ag Novel 6,7-dihydropyrido[2,1-a]phthalazin-2-ones for the treatment and prophylaxis of hepatitis b virus infection
CN107759585A (zh) * 2016-07-29 2018-03-06 银杏树药业(苏州)有限公司 一种异喹啉类化合物及其药用组合物和作为抗病毒药物的应用

Also Published As

Publication number Publication date
HRP20211331T1 (hr) 2021-11-26
PT3590942T (pt) 2021-07-28
HUE055170T2 (hu) 2021-11-29
EA201992082A1 (ru) 2020-02-12
JP6783424B2 (ja) 2020-11-11
AU2018232071A1 (en) 2019-10-17
AU2018232071B2 (en) 2021-07-08
SG11201908101YA (en) 2019-10-30
EA038122B9 (ru) 2021-09-14
US20200039995A1 (en) 2020-02-06
CN109071564A (zh) 2018-12-21
MX2019010736A (es) 2019-11-05
CA3055442C (en) 2021-03-23
IL269142B (en) 2020-07-30
CA3055442A1 (en) 2018-09-13
EP3590942B1 (en) 2021-06-09
PL3590942T3 (pl) 2021-12-13
PH12019502052A1 (en) 2020-07-06
BR112019018650A2 (pt) 2020-04-07
KR20190117799A (ko) 2019-10-16
EA038122B1 (ru) 2021-07-09
WO2018161960A1 (zh) 2018-09-13
BR112019018650B1 (pt) 2021-12-14
JP2020509075A (ja) 2020-03-26
MX374497B (es) 2025-03-06
EP3590942A4 (en) 2020-01-08
RS62094B1 (sr) 2021-08-31
MY174224A (en) 2020-03-23
DK3590942T3 (da) 2021-09-06
PH12019502052B1 (en) 2023-09-08
ES2879930T3 (es) 2021-11-23
ZA201906252B (en) 2021-04-28
EP3590942A1 (en) 2020-01-08
SI3590942T1 (sl) 2021-11-30
US11008331B2 (en) 2021-05-18
KR102087397B1 (ko) 2020-03-11
CN109071564B (zh) 2019-08-27

Similar Documents

Publication Publication Date Title
DK3590942T3 (da) Hepatitis B-virusoverfladeantigeninhibitor
IL282985B (en) Modified oncolytic viurs
IL259077A (en) Vaccines against hepatitis b virus
IL280459A (en) Phosphoramidates for the treatment of hepatitis b virus
IL282881A (en) Methods for treating hepatitis b infection
DK3565568T3 (da) Ændret virus
IL262922B (en) Adeno-associated virus variant capsids and methods of use thereof
EP3632914A4 (en) HEPATITIS B VIRUS SURFACE ANTI-INHIBITORS
SI3480307T1 (sl) Nov gensko spremenjen virus vakcinije
EP3863043A4 (en) SUSCEPTOR
PT3468990T (pt) Anticorpos anti-c5 e utilizações dos mesmos
EP3393506C0 (en) VIRUS PURIFICATION PROCESS
IL284044A (en) Antibodies that neutralize hepatitis b virus and uses thereof
DK3609535T3 (da) Hbv-vaccine
IL279537A (en) Aav compositions
SG11201605691VA (en) Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
DK3463001T3 (da) Kogegrej
EP3849328C0 (en) MICROEMULSIONS CONTAINING ANTIOXIDANTS
EP3627536A4 (en) SUSCEPTOR
EP3625349A4 (en) MODIFIED VIRUSES
DK3263590T3 (da) Fiskevirus
EP3428946A4 (en) MAGNETRON
EP3435402A4 (en) MAGNETRON
DK3599479T3 (da) Projektildetektering
GB201702193D0 (en) Hepatitis E virus vaccine